59237-53-5

Usage

Uses

Used in Pharmaceutical Industry:
Methyl-6-chloro-5-nitronicotinate is used as a building block for the synthesis of various pharmaceutical compounds, particularly anticoccidial agents. Its chemical structure allows for the development of drugs that target and combat parasitic infections, such as coccidiosis, which is a significant concern in the poultry industry.
The application of Methyl-6-chloro-5-nitronicotinate in the pharmaceutical industry is primarily due to its ability to be incorporated into the molecular structure of anticoccidial agents. This enables the creation of effective treatments for parasitic infections, which can have a significant impact on the health and productivity of livestock.

InChI:InChI=1/C7H5ClN2O4/c1-14-7(11)4-2-5(10(12)13)6(8)9-3-4/h2-3H,1H3

Upstream product

• 67-56-1 methanol 
• 23945-84-8 6-chloro-5-nitro-nicotinoyl chloride 
• 6635-31-0 6-hydroxy-5-nitronicotinic acid 
• 7477-10-3 6-chloro-5-nitronicotinic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 166742-22-9 methyl 6-(methylthio)-5-nitronicotinate 
• 59237-49-9 6-methoxy-5-nitro-nicotinic acid methyl ester 
• 211915-52-5 methyl 6-(methylamino)-5-nitronicotinate 
• 104685-75-8 methyl 2-amino-3-nitropyridine-5-carboxylate 
• 1354829-72-3 tert-butyl 3-[(6-benzylsulfanyl-5-nitropyridine-3-carbonyl)amino]propionate 
• 1354829-71-2 6-benzylsulfanyl-5-nitronicotinic acid 
• 1354829-70-1 methyl 6-benzylsulfanyl-5-nitronicotinate 

Relevant academic research and scientific papers

3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity

Several retinoid X receptor (RXR) ligands (rexinoids), such as bexarotene (1), exhibit teratogenicity, which is a serious impediment to their clinical application. We considered that rexinoids with a lower level of maximal RXR transcription activation (i.e., partial agonists) and lower lipid solubility might show weaker adverse side effects. Based on this idea, we modified our previously reported pentamethyltetralin-type RXR partial agonists 5 and 6 to reduce their lipophilicity. Here, we report a new RXR partial agonist, 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-2-(trifluoromethyl)-3H-imidazo[4,5-b]pyridine-6-carboxylic acid (8, CATF-PMN), which showed greatly reduced teratogenicity in zebrafish embryos.

Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer Models

ATAD2 is an epigenetic bromodomain-containing target which is overexpressed in many cancers and has been suggested as a potential oncology target. While several small molecule inhibitors have been described in the literature, their cellular activity has proved to be underwhelming. In this work, we describe the identification of a novel series of ATAD2 inhibitors by high throughput screening, confirmation of the bromodomain region as the site of action, and the optimization campaign undertaken to improve the potency, selectivity, and permeability of the initial hit. The result is compound 5 (AZ13824374), a highly potent and selective ATAD2 inhibitor which shows cellular target engagement and antiproliferative activity in a range of breast cancer models.

Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype

We describe our efforts to introduce structural diversity to a previously described triazole-containing N1-carboline series of bromodomain and extra-terminal (BET) inhibitors. N9 carbolines were designed to retain favorable binding interactions that the N1-carbolines possess. A convergent synthetic route enabled modifications to reduce clearance, enhance physicochemical properties, and improve the overall in vitro profile. This work led to the identification of a potent BET inhibitor, (S)-2‐{8‐fluoro‐5‐[(3‐fluoropyridin‐2‐yl)(oxan‐4‐yl)methyl]‐7‐[4‐(2H3)methyl‐1‐methyl‐1H‐1,2,3‐triazol‐5‐yl]‐5H‐pyrido[3,2‐b]indol‐3‐yl}propan‐2‐ol (10), a compound with enhanced oral exposure in mice. Subsequent evaluation in a mouse triple-negative breast cancer tumor model revealed efficacy at 4 mg/kg of N9-carboline 10.

NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND APPLICATION THEREFOR

[Problems] To provide a novel peptide synthesis technique that is completely different than heretofore, and to provide a novel compound that enables the synthesis/creation of a novel artificial functional protein and the synthesis/creation of a novel functional peptide, as well as a method for producing the same. [Solution] A compound represented by formula (I) or a salt thereof.

TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases

New pyridin-2(1h)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES

Compoundshaving the chemical structure of formula (I) are disclosed; as well as process for theirpreparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

Development of a solid-supported biotinylation reagent for efficient biotin labeling of SH groups on small molecules

We report here the design and synthesis of a novel and selective SH-group biotinylating reagent, KSH-1 (1), for the biotinylation of small molecules using solid phase chemistry. The results demonstrate that 1 efficiently biotinylated a small molecule, cap

THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS

Provided herein are novel sirtuin-modulating compounds of Structural Formula (Ia) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES

This invention provides compounds of Formula I which are PAFR antagonists: I and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preve